Acquisition will strengthen MYND’s psilocybin-assisted medicinal and diagnostics capabilities, adding novel psychedelics for the treatment of dementia, including Alzheimer’s disease. VANCOUVER, BC, Dec. 17, 2021 /CNW/ – Further to news release of October 27, 2021, MYND Life Sciences Inc. (“MYND“)(CSE: MYND) (OTC: MYNDF) is pleased to announce it has successfully closed on the previously announced…


Previous articlePTSF89 – A Macro Dive Into Microdosing
Next articlePsychedelic Bulletin: COMPASS’ “Infamous” Psilocybin Patent Challenged; atai Stock Price Tumbles As Lock-Up Expiry Date Arrives; UT Austin Launches Psychedelics Centre